** Hong Kong shares of InnoCare Pharma 9969.HK jump 11.5% to HK$7.25, highest since November 13, 2024
** Shanghai-listed stock 688428.SS rises 7.1% to 13.68 yuan, highest since December 16, 2024
** China's National Medical Products Administration (NMPA) approves registrational Phase III study of drug used to treat a form of blood cancer
** Hong Kong-listed stock fell 11.2% last year, while Shanghai stock rose 6.8%
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。